Drug
Ambrisentan clinical trials
Also written Letairis, Volibris, GSK1325760A and BSF 208075.
- studies test it
- 55
- open now
- 4
- in phase 3
- 20
- first study started
- 2002
Keep track of what changes. Save the ambrisentan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
55 studies that test it; most in 2008 (7)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 7 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 18
- Phase 3
- 20
- Phase 4
- 9
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 32
Gilead Sciences (12) · GlaxoSmithKline (8) · Noorik Biopharmaceuticals AG (3) · RenJi Hospital (2) · Brigham and Women's Hospital (2) · Medical University of South Carolina (2) · Nanjing First Hospital, Nanjing Medical University (2) · Cambridge University Hospitals NHS Foundation Trust (1)
Often tested with
Tested in the same studies.
Tadalafil (3) · Aminophylline (2) · Bosentan (2) · Prevotella histicola EDP1815 (1) · Dapagliflozin (1) · Omega-N-Methylarginine (1) · Theophylline (1) · Spironolactone (1)
Studies
Open first, then newest update. How each study uses ambrisentan is read from its arms, and is right about nine times in ten.
Testing it · 55
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07245680Written as Ambrisentan
- Comparison of Sequential to Initial Combination Therapy in PAHRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06968962Written as Ambrisentan
- Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionNot yet recruitingNot applicableNanjing First Hospital, Nanjing Medical UniversityNCT06987097Written as Ambrisentan
- Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial HypertensionRecruitingNot applicableNanjing First Hospital, Nanjing Medical UniversityNCT04972656Written as Ambrisentan
- Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal SyndromeActive, not recruitingPhase 2Noorik Biopharmaceuticals AGNCT06256432Written as Ambrisentan
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and MechanismsCompletedPhase 2/3Cambridge University Hospitals NHS Foundation TrustNCT04393246Written as Ambrisentan
- A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19TerminatedPhase 2Noorik Biopharmaceuticals AGNCT04771000Written as Ambrisentan
- Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529CompletedPhase 2GlaxoSmithKlineNCT01342952Written as Ambrisentan
- Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial HypertensionCompletedPhase 3RenJi HospitalNCT05437224Written as Ambrisentan
- An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)CompletedPhase 4Brigham and Women's HospitalNCT01338636Written as Ambrisentan
- Mechanisms of Cerebrovascular ControlCompletedPhase 1University of Wisconsin, MadisonNCT02936687Written as ET-1 Inhibition
- A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver CirrhosisTerminatedPhase 2Noorik Biopharmaceuticals AGNCT03827200Written as Ambrisentan
- Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial HypertensionTerminatedNot applicableNational Jewish HealthNCT02169752Written as Ambrisentan
- Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label TrialCompletedPhase 3Tufts Medical CenterNCT01224210Written as Ambrisentan
- Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With AmbrisentanCompletedPhase 4University of California, Los AngelesNCT01051960Written as Ambrisentan
- Study of Ambrisentan in Participants With Pulmonary HypertensionCompletedPhase 3Gilead SciencesNCT00777920Written as Ambrisentan
- Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial HypertensionStatus unknownPhase 1/2RenJi HospitalNCT04528056Written as Ambrisentan
- Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing SurgeryStatus unknownPhase 2Bnai Zion Medical CenterNCT04450095Written as Ambrisentan 10 MG
- Safety and Efficacy Trial to Treat Diastolic Heart Failure Using AmbrisentanTerminatedPhase 4University of Texas Southwestern Medical CenterNCT00840463Written as Ambrisentan
- Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)CompletedPhase 2Heidelberg UniversityNCT02290613Written as Ambrisentan
Codes
What other systems call ambrisentan · ClinicalTrials.gg INT004484
- MeSH (NLM) C467894ambrisentanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HW6NV07QECAMBRISENTANConfirmed FDA, NLM, Wikidata
- UNII (FDA) 7B43003091AMBRISENTAN, (+/-)-Confirmed NLM, Wikidata
- RxNorm 358274Confirmed FDA, Wikidata
- Wikidata Q410789ambrisentanConfirmed FDA, NLM, Wikidata
- Wikidata Q27166204(+/-)-ambrisentanConfirmed NLM, Wikidata
- NCI Thesaurus C72694AmbrisentanOne source FDA
- DrugBank DB06403One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C467894 | ambrisentan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HW6NV07QEC | AMBRISENTAN | Confirmed FDA, NLM, Wikidata |
| UNII (FDA) | 7B43003091 | AMBRISENTAN, (+/-)- | Confirmed NLM, Wikidata |
| RxNorm | 358274 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410789 | ambrisentan | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27166204 | (+/-)-ambrisentan | Confirmed NLM, Wikidata |
| NCI Thesaurus | C72694 | Ambrisentan | One source FDA |
| DrugBank | DB06403 | — | One source Wikidata |
Also registered as ambrisentan, (r)- (UNII Q1BX7HE63A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.